^(125)I放射性粒子植入治疗腹膜后转移瘤患者的临床疗效观察

Clinical effect oberservation on^(125)I radioactive particle implantation in the treatment of retroperitoneal metastasis

目的探讨^(125)I放射性粒子植入治疗腹膜后转移瘤患者的临床疗效。方法选取2020年1月至2023年12月湖北中医药大学附属医院(湖北省中医院)的腹膜后转移瘤患者26例,根据随机数字表法,将患者分为观察组和对照组,每组13例。观察组接受盐酸羟考酮缓释片联合^(125)I粒子植入治疗,其中^(125)I粒子剂量10183.9~13296.1 cGy,平均(12485.7±405.2)cGy;对照组仅接受盐酸羟考酮缓释片镇痛治疗,两组均治疗3个月。分别采用疼痛数字评价量表(numeric rating scale,NRS)和欧洲癌症研究与治疗组织生命质量测量量表核心30项(the European Organization for Re⁃search and Treatment of Cancer Quality of Life Questionnaire-Core 30,EORTCQLQ-C30)评估患者的疼痛情况和生命质量。比较治疗前后两组疼痛情况、每日镇痛药需求量、生活质量以及不良反应的发生率。结果26例患者中男16例、女10例,年龄52~71岁,平均(56.1±5.9)岁。治疗后1个月、2个月、3个月,与对照组相比,观察组NRS评分和每日镇痛药需求量较低;治疗后3个月,与对照组相比,观察组疼痛缓解率较高、不良反应发生率较低,EORTCQLQ-C30总分较高,差异均有统计学意义(P<0.05)。结论^(125)I放射性粒子植入治疗可有效缓解腹膜后转移瘤患者疼痛情况,并改善生活质量,安全性高。

Objective To explore the clinical effect of^(125)I radioactive particle implantation in the treatment of retroperitoneal metastasis.Methods A total of 26 patients with retroperitoneal metastasis admitted to the Affiliated Hospital of Hubei University of Chinese Medicine(Hubei Provincial Hospital of Chinese Medicine)from January 2020 to December 2023 were selected,and were divided into observation group and control group according to the random number table,with 13 patients in each group.The observation group received sustained-release oxycodone hydrochloride tablets combined with^(125)I radioactive particle implantation,in which the dose of^(125)I was 10183.9-13296.1 cGy,with an average of(12485.7±405.2)cGy.The control group only received sustained-release oxycodone hydrochloride tablets.Both groups were treated for three months.The numeric rating scale(NRS)and the European Organization for Research and Treatment of Cancer Quality of Life Questionnarie-Core 30(EORTCQLQ-C30)were used to evaluate the pain status and quality of life of the patients,respectively.The pain,daily demand for analgesics,quality of life and the incidence of adverse reactions were compared between the two groups before and after treatment.Results Among the 26 patients,there were 16 males and 10 females,aged from 52 to 71 years,with an average age of(56.1±5.9)years.Compare with the control group,the NRS scores and daily analgesic demand in the observation group were lower at one month,two months and three months after treatment,while the pain relief rate was higher,the incidence of adverse reactions was lower and the total score of EORTCQLQ-C30 was higher in the observation group than those of the control group after three months of treatment,the differrences were statistically significant(all P<0.05).Conclusions^(125)I radioactive particle implantation can effectively relieve the pain and improve the quality of life of the patients with retroperitoneal metastatic,with high safety.